Abstract
The Global Initiative for Asthma recommends gradually stepping down treatments to the lowest oral/inhaled corticosteroid doses that control symptoms and exacerbations. Tezepelumab treatment enabled reductions in oral/inhaled corticosteroid doses versus placebo, while preserving asthma symptom control and lung function.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have